Amicus TherapeuticsFOLD
About: Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Employees: 499
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
4% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 101
2% less call options, than puts
Call options by funds: $4.77M | Put options by funds: $4.87M
7% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 42
1.36% less ownership
Funds ownership: 103.45% [Q3] → 102.09% (-1.36%) [Q4]
2% less funds holding
Funds holding: 287 [Q3] → 282 (-5) [Q4]
12% less capital invested
Capital invested by funds: $3.28B [Q3] → $2.87B (-$403M) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 6 [Q3] → 4 (-2) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Wells Fargo Tiago Fauth 32% 1-year accuracy 9 / 28 met price target | 121%upside $17 | Overweight Maintained | 20 Feb 2025 |
Financial journalist opinion
Based on 7 articles about FOLD published over the past 30 days
